Bay Area oncology company Sutro Biopharma received a second investment from Amgen Ventures as part of an $85 million Series E funding round. The funding will support Phase 1 clinical testing for two products intended to treat ovarian and endometrial cancer and multiple myeloma. Samsara BioCapital and Surveyor Capital led the investment, which got participation…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
